8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Feb 12, 2026·SEC
Material company update
Jan 12, 2026·SEC
Agios Pharmaceuticals, Inc.(AGIO)Earnings, Financials & Key Ratios
AGIO•NASDAQ
$27.21
$1.62B mkt cap·Price updated May 6, 2026
AboutAgios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$54M+48.0%
- EBITDA-$467M-11.2%
- Net Income-$413M-161.3%
- EPS (Diluted)-7.12-161.2%
- Gross Margin78.67%-11.2%
- EBITDA Margin-864.28%+24.9%
- Operating Margin-873.87%+25.1%
- Net Margin-764.01%-141.4%
- ROE-30.2%-152.7%
- ROIC-26.35%+4.4%
- Debt/Equity0.05+40.6%
AGIO Key Insights
Agios Pharmaceuticals, Inc. (AGIO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AGIO Price & Volume
Agios Pharmaceuticals, Inc. (AGIO) stock price & volume — 10-year historical chart
Loading chart...
AGIO Growth Metrics
Agios Pharmaceuticals, Inc. (AGIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-0.9%
5 Years-
3 Years55.97%
TTM78.34%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-163.46%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-164.22%
Return on Capital
10 Years-43.27%
5 Years-34.53%
3 Years-35.59%
Last Year-33.76%
AGIO Recent Earnings
Agios Pharmaceuticals, Inc. (AGIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Apr 29, 2026EPS
$1.69
Est $1.81
+6.6%
Revenue
$21M
Est $13M
+56.0%
Q1 2026
Feb 12, 2026EPS
$1.85
Est $1.97
+6.1%
Revenue
$20M
Est $12M
+65.1%
Q4 2025
Oct 30, 2025EPS
$1.78
Est $1.93
+7.8%
Revenue
$13M
Est $12M
+10.1%
Q3 2025
Jul 31, 2025EPS
$1.93
Est $1.74
-10.9%
Revenue
$12M
Est $10M
+21.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $1.69vs $1.81+6.6% | $21Mvs $13M+56.0% |
| Q1 2026 | Feb 12, 2026 | $1.85vs $1.97+6.1% | $20Mvs $12M+65.1% |
| Q4 2025 | Oct 30, 2025 | $1.78vs $1.93+7.8% | $13Mvs $12M+10.1% |
| Q3 2025 | Jul 31, 2025 | $1.93vs $1.74-10.9% | $12Mvs $10M+21.2% |
Based on last 12 quarters of dataView full earnings history →
AGIO Peer Comparison
Agios Pharmaceuticals, Inc. (AGIO) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IONS | 12.44B | 75.25 | -31.62 | 33.87% | -30.87% | -58.57% | 5.35 | |
 PTCT | 5.39B | 65.04 | 8.36 | 114.51% | 39.44% | 13.02% | ||
 RARE | 2.46B | 25.01 | -4.29 | 20.13% | -85.54% | -9.11% | ||
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 RYTM | 6.3B | 92.31 | -29.68 | 45.83% | -93.84% | -204.35% | 1.77 | |
 SRPT | 2.28B | 21.79 | 9.31 | 52.97% | -11.25% | -20.57% | 0.88 | |
 BMRN | 10.24B | 53.24 | 29.58 | 12.87% | 8.29% | 4.41% | 7.08% | 0.11 |
Compare AGIO vs Peers
Agios Pharmaceuticals, Inc. (AGIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AGIO Income Statement
Agios Pharmaceuticals, Inc. (AGIO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 43.01M | 94.39M | 117.91M | 0 | 0 | 14.24M | 26.82M | 36.5M | 54.03M | 66.05M |
| Revenue Growth % | -38.46% | 119.45% | 24.92% | -100% | - | - | 88.36% | 36.07% | 48.03% | 78.34% |
| Cost of Goods Sold | 292.68M | 1.4M | 1.32M | 18.77M | 18.78M | 1.7M | 9.5M | 4.17M | 11.52M | 11.84M |
| COGS % of Revenue | 680.48% | 1.48% | 1.12% | - | - | 11.97% | 35.43% | 11.41% | 21.33% | - |
| Gross Profit | -249.67M▲ 0% | 92.99M▲ 137.2% | 116.59M▲ 25.4% | -18.77M▼ 116.1% | -18.78M▼ 0.0% | 12.54M▲ 166.8% | 17.32M▲ 38.2% | 32.33M▲ 86.7% | 42.51M▲ 31.5% | 54.21M▲ 0% |
| Gross Margin % | -580.48% | 98.52% | 98.88% | - | - | 88.03% | 64.57% | 88.59% | 78.67% | 82.07% |
| Gross Profit Growth % | -66.15% | 137.25% | 25.38% | -116.1% | -0.03% | 166.76% | 38.15% | 86.69% | 31.46% | - |
| Operating Expenses | 363.81M | 455.47M | 542.93M | 317.14M | 359.64M | 401.58M | 408.81M | 458.07M | 514.64M | 529.74M |
| OpEx % of Revenue | 845.84% | 482.55% | 460.45% | - | - | 2820.11% | 1524.09% | 1255.06% | 952.54% | - |
| Selling, General & Admin | 71.12M | 114.14M | 132.03M | 106.12M | 121.44M | 121.67M | 119.9M | 156.78M | 180.28M | 187.06M |
| SG&A % of Revenue | 165.36% | 120.93% | 111.98% | - | - | 854.45% | 447.02% | 429.57% | 333.68% | - |
| Research & Development | 292.68M | 341.32M | 410.89M | 211.02M | 256.97M | 279.91M | 288.9M | 301.29M | 334.36M | 342.68M |
| R&D % of Revenue | 680.48% | 361.62% | 348.48% | - | - | 1965.66% | 1077.07% | 825.49% | 618.86% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -18.78M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -320.79M▲ 0% | -362.48M▼ 13.0% | -426.33M▼ 17.6% | -335.92M▲ 21.2% | -378.42M▼ 12.7% | -389.05M▼ 2.8% | -391.49M▼ 0.6% | -425.74M▼ 8.7% | -472.13M▼ 10.9% | -475.53M▲ 0% |
| Operating Margin % | -745.84% | -384.03% | -361.57% | - | - | -2732.07% | -1459.52% | -1166.47% | -873.87% | -719.97% |
| Operating Income Growth % | -59.61% | -12.99% | -17.62% | 21.21% | -12.65% | -2.81% | -0.63% | -8.75% | -10.9% | - |
| EBITDA | -314.36M | -355.31M | -409.71M | -317.14M | -359.64M | -380.48M | -384.86M | -420.08M | -466.95M | -470.27M |
| EBITDA Margin % | -730.89% | -376.44% | -347.47% | - | - | -2671.93% | -1434.83% | -1150.98% | -864.28% | -712.01% |
| EBITDA Growth % | -60.98% | -13.02% | -15.31% | 22.59% | -13.4% | -5.8% | -1.15% | -9.15% | -11.16% | -8.18% |
| D&A (Non-Cash Add-back) | 6.43M | 7.17M | 16.62M | 18.77M | 18.78M | 8.56M | 6.62M | 5.65M | 5.18M | 5.26M |
| EBIT | -320.79M | -346.03M | -411.47M | -329.31M | -356.51M | -389.05M | -391.49M | -425.74M | -472.13M | -475.53M |
| Net Interest Income | 6.12M | 16.45M | 14.86M | -11.22M | 836K | 12.79M | 33.34M | 48.08M | 56.38M | 51.09M |
| Interest Income | 6.12M | 16.45M | 14.86M | 6.61M | 836K | 12.79M | 33.34M | 48.08M | 56.38M | 51.09M |
| Interest Expense | 0 | 0 | 0 | 17.83M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 6.12M | 16.45M | 14.86M | 6.61M | 21.91M | 157.25M | 39.4M | 1.14B | 58.34M | 51.91M |
| Pretax Income | -314.67M▲ 0% | -346.03M▼ 10.0% | -411.47M▼ 18.9% | -329.31M▲ 20.0% | -356.51M▼ 8.3% | -231.8M▲ 35.0% | -352.09M▼ 51.9% | 717.97M▲ 303.9% | -413.8M▼ 157.6% | -423.62M▲ 0% |
| Pretax Margin % | -731.6% | -366.61% | -348.97% | - | - | -1627.82% | -1312.63% | 1967.15% | -765.89% | -641.38% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 44.24M | -1.02M | -1.02M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 6.16% | 0.25% | 0.24% |
| Net Income | -314.67M▲ 0% | -346.03M▼ 10.0% | -411.47M▼ 18.9% | -327.37M▲ 20.4% | 1.6B▲ 590.2% | -231.8M▼ 114.4% | -352.09M▼ 51.9% | 673.73M▲ 291.4% | -412.78M▼ 161.3% | -422.6M▲ 0% |
| Net Margin % | -731.6% | -366.61% | -348.97% | - | - | -1627.82% | -1312.63% | 1845.92% | -764.01% | -639.84% |
| Net Income Growth % | -58.55% | -9.97% | -18.91% | 20.44% | 590.18% | -114.44% | -51.89% | 291.35% | -161.27% | -163.46% |
| Net Income (Continuing) | -314.67M | -346.03M | -411.47M | -329.31M | -356.51M | -231.8M | -352.09M | 673.73M | -412.78M | -422.6M |
| Discontinued Operations | 0 | 0 | 0 | 1.94M | 1.96B | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -6.75▲ 0% | -6.03▲ 10.7% | -6.61▼ 9.6% | -4.74▲ 28.3% | -6.36▼ 34.2% | -4.23▲ 33.5% | -6.33▼ 49.6% | 11.64▲ 283.9% | -7.12▼ 161.2% | -7.19▲ 0% |
| EPS Growth % | -33.14% | 10.67% | -9.62% | 28.29% | -34.18% | 33.49% | -49.65% | 283.89% | -161.17% | -164.22% |
| EPS (Basic) | -6.75 | -6.03 | -6.61 | -4.74 | -6.36 | -4.23 | -6.33 | 11.86 | -7.12 | - |
| Diluted Shares Outstanding | 46.59M | 57.42M | 59.99M | 69M | 60.45M | 54.79M | 55.65M | 57.89M | 57.97M | 58.78M |
| Basic Shares Outstanding | 46.59M | 57.42M | 59.99M | 69M | 60.45M | 54.79M | 55.65M | 56.81M | 57.97M | 58.78M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AGIO Balance Sheet
Agios Pharmaceuticals, Inc. (AGIO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 445.26M | 613.78M | 611.7M | 636.68M | 1.06B | 832.77M | 833.84M | 965.6M | 942.05M | 834.84M |
| Cash & Short-Term Investments | 567.75M | 805.42M | 564.88M | 572.93M | 1.02B | 783.12M | 776.93M | 893.71M | 854.42M | 737.04M |
| Cash Only | 567.75M | 805.42M | 80.93M | 127.44M | 203.13M | 139.26M | 88.2M | 76.25M | 89.13M | 113.6M |
| Short-Term Investments | 0 | 0 | 483.95M | 445.49M | 816.89M | 643.86M | 688.72M | 817.46M | 765.29M | 623.44M |
| Accounts Receivable | 3.67M | 10.44M | 15.32M | 0 | 4.38M | 2.21M | 2.81M | 4.11M | 10.58M | 16.13M |
| Days Sales Outstanding | 31.14 | 40.38 | 47.42 | - | - | 56.54 | 38.24 | 41.09 | 71.46 | 50.74 |
| Inventory | -143.81M | 869K | 7.33M | 0 | 0 | 8.49M | 19.08M | 27.62M | 32.92M | 35.09M |
| Days Inventory Outstanding | - | 227.05 | 2.03K | - | - | 1.82K | 732.61 | 2.42K | 1.04K | 1.01K |
| Other Current Assets | 0 | 17.17M | 0 | 63.75M | 0 | 38.95M | 35.02M | 40.16M | 44.13M | 46.59M |
| Total Non-Current Assets | 169.14M | 244.68M | 279.04M | 216.27M | 373.5M | 405.95M | 103.28M | 697.6M | 355.17M | 350.15M |
| Property, Plant & Equipment | 24.43M | 24.32M | 126.11M | 116.07M | 104.23M | 88.12M | 69.79M | 54.55M | 41.23M | 37.76M |
| Fixed Asset Turnover | 1.76x | 3.88x | 0.94x | - | - | 0.16x | 0.38x | 0.67x | 1.31x | 1.55x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 143.81M | 220.12M | 152.93M | 97.61M | 266.38M | 313.87M | 29.43M | 638.32M | 310.01M | 1.32B |
| Other Non-Current Assets | 891K | 238K | 0 | 2.6M | 2.9M | 3.96M | 4.06M | 4.72M | 3.93M | 15.73M |
| Total Assets | 614.4M▲ 0% | 858.46M▲ 39.7% | 890.74M▲ 3.8% | 852.95M▼ 4.2% | 1.44B▲ 68.6% | 1.24B▼ 13.8% | 937.12M▼ 24.3% | 1.66B▲ 77.5% | 1.3B▼ 22.0% | 1.18B▲ 0% |
| Asset Turnover | 0.07x | 0.11x | 0.13x | - | - | 0.01x | 0.03x | 0.02x | 0.04x | 0.05x |
| Asset Growth % | -0.76% | 39.72% | 3.76% | -4.24% | 68.56% | -13.84% | -24.35% | 77.48% | -22% | 21.82% |
| Total Current Liabilities | 94.94M | 93.5M | 92.89M | 94.39M | 59.83M | 62.63M | 67.95M | 81.16M | 82.21M | 58.84M |
| Accounts Payable | 22.77M | 17.88M | 21.9M | 17.72M | 16.7M | 18.62M | 9.78M | 16.64M | 18.36M | 13.75M |
| Days Payables Outstanding | 28.39 | 4.67K | 6.07K | 344.62 | 324.63 | 3.99K | 375.6 | 1.46K | 581.46 | 533.17 |
| Short-Term Debt | 0 | 0 | 0 | 7.41M | 0 | 0 | 0 | 0 | 18.39M | 18.8M |
| Deferred Revenue (Current) | 163.64M | 92.52M | 10.93M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 18.64M | 22.07M | 18.98M | 48.91M | 19.82M | 12.24M | 23.23M | 46.86M | 18.2M | 14.61M |
| Current Ratio | 4.69x | 6.56x | 6.59x | 6.74x | 17.79x | 13.30x | 12.27x | 11.90x | 11.46x | 11.46x |
| Quick Ratio | 6.20x | 6.55x | 6.51x | 6.74x | 17.79x | 13.16x | 11.99x | 11.56x | 11.06x | 11.06x |
| Cash Conversion Cycle | - | -4.4K | -3.99K | - | - | -2.11K | 395.25 | 1K | 532.85 | 526.23 |
| Total Non-Current Liabilities | 143.95M | 77.42M | 157.33M | 359.06M | 85.94M | 75.28M | 58.14M | 41.09M | 21.91M | 17.03M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21.82M | 0 |
| Capital Lease Obligations | 0 | 0 | 106.75M | 97.79M | 85.94M | 72M | 56.99M | 40.21M | 21.82M | 96.45M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 18.16M | 17.61M | 0 | 261.27M | 0 | 3.28M | 1.16M | 880K | -21.73M | 371K |
| Total Liabilities | 238.89M | 170.92M | 250.21M | 453.45M | 145.76M | 137.9M | 126.1M | 122.24M | 104.11M | 75.88M |
| Total Debt | 0 | 0 | 113.66M | 105.2M | 97.09M | 85.66M | 72M | 56.99M | 62.02M | 35.74M |
| Net Debt | -567.75M | -805.42M | 32.73M | -22.24M | -106.03M | -53.6M | -16.21M | -19.26M | -27.11M | -77.86M |
| Debt / Equity | - | - | 0.18x | 0.26x | 0.08x | 0.08x | 0.09x | 0.04x | 0.05x | 0.05x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.08x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.17x |
| Interest Coverage | - | - | - | -18.47x | - | - | - | - | - | - |
| Total Equity | 375.5M▲ 0% | 687.54M▲ 83.1% | 640.53M▼ 6.8% | 399.5M▼ 37.6% | 1.29B▲ 223.4% | 1.1B▼ 14.8% | 811.02M▼ 26.3% | 1.54B▲ 90.0% | 1.19B▼ 22.6% | 1.11B▲ 0% |
| Equity Growth % | 4.72% | 83.1% | -6.84% | -37.63% | 223.4% | -14.8% | -26.33% | 90% | -22.57% | 39.36% |
| Book Value per Share | 8.06 | 11.97 | 10.68 | 5.79 | 21.37 | 20.09 | 14.57 | 26.62 | 20.58 | 18.87 |
| Total Shareholders' Equity | 375.5M | 687.54M | 640.53M | 399.5M | 1.29B | 1.1B | 811.02M | 1.54B | 1.19B | 1.11B |
| Common Stock | 49K | 58K | 68K | 69K | 71K | 71K | 72K | 73K | 75K | 76K |
| Retained Earnings | -798.06M | -1.1B | -1.52B | -1.84B | -238.76M | -470.56M | -822.65M | -148.92M | -561.71M | -660.82M |
| Treasury Stock | 0 | 0 | 0 | 0 | -802.49M | -802.49M | -802.49M | -802.49M | -802.49M | -802.49M |
| Accumulated OCI | -1.39M | -2.17M | 202K | 105K | -1.2M | -12.54M | -441K | -1.52M | 2.19M | -314K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AGIO Cash Flow Statement
Agios Pharmaceuticals, Inc. (AGIO) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -285.23M | -304.42M | -370.62M | -290.76M | -407.32M | -309.48M | -296.06M | -389.84M | -372.98M | -372.98M |
| Operating CF Margin % | -663.16% | -322.52% | -314.32% | - | - | -2173.3% | -1103.76% | -1068.12% | -690.34% | - |
| Operating CF Growth % | -839.67% | -6.73% | -21.75% | 21.55% | -40.09% | 24.02% | 4.33% | -31.68% | 4.33% | 10.17% |
| Net Income | -314.67M | -346.03M | -411.47M | -329.31M | -356.51M | -231.8M | -352.09M | 673.73M | -412.78M | -422.6M |
| Depreciation & Amortization | 6.43M | 7.17M | 8.09M | 18.77M | 9.24M | 8.56M | 6.62M | 5.65M | 5.18M | 5.26M |
| Stock-Based Compensation | 47.81M | 73.36M | 72.37M | 0 | 53.51M | 49.3M | 44.77M | 42.85M | 52.55M | 56.73M |
| Deferred Taxes | 0 | 0 | -2.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 29K | -3.82M | 8.53M | 17.81M | -76.74M | -119.1M | 23.69M | -1.09B | 15.12M | 15.54M |
| Working Capital Changes | -24.83M | -35.1M | -46M | 1.97M | -36.82M | -16.43M | -19.06M | -19.77M | -33.04M | -35.34M |
| Change in Receivables | 1.22M | -6.1M | -3.62M | 0 | -4.38M | -2.21M | -604K | -1.3M | -6.47M | -12.79M |
| Change in Inventory | -2.08M | -869K | -6.46M | -7.37M | 0 | -8.49M | -10.58M | -8.54M | -5.3M | -5.48M |
| Change in Payables | 5.33M | -5.49M | 3.72M | 3.33M | 1.86M | 3.44M | -8.73M | 6.6M | 1.75M | -426K |
| Cash from Investing | -57.91M | -273.82M | 91.44M | 75.75M | 1.25B | 243.26M | 239.57M | 363.44M | 377.18M | 405.91M |
| Capital Expenditures | -4.63M | -6.99M | -12.17M | -14.11M | -5.74M | -4.88M | -999K | -1.69M | -4.32M | -4.32M |
| CapEx % of Revenue | 10.76% | 7.4% | 10.32% | - | - | 34.28% | 3.72% | 4.62% | 7.99% | - |
| Acquisitions | 0 | 0 | -103.47M | 0 | 0 | 132.75M | 0 | 40K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -53.28M | -266.84M | 103.47M | -803K | 1.8B | 0 | -16.18M | 1.09B | -10M | -10M |
| Cash from Financing | 285.11M | 546.02M | 289.61M | 261.52M | -765.77M | 2.35M | 5.43M | 14.44M | 8.68M | 9.13M |
| Debt Issued (Net) | 0 | 0 | -113K | -336K | -578K | -331K | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 270.25M | 516.21M | 277.2M | 11.32M | -802.49M | 2.68M | 5.43M | 14.44M | 8.68M | 9.13M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -802.49M | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 14.86M | 29.82M | 12.52M | 250.54M | 37.3M | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | -58.03M▲ 0% | -32.22M▲ 44.5% | 10.43M▲ 132.4% | 46.51M▲ 345.9% | 75.69M▲ 62.8% | -63.87M▼ 184.4% | -51.05M▲ 20.1% | -11.96M▲ 76.6% | 12.88M▲ 207.7% | 34.64M▲ 0% |
| Free Cash Flow | -289.86M▲ 0% | -311.41M▼ 7.4% | -382.79M▼ 22.9% | -304.87M▲ 20.4% | -413.06M▼ 35.5% | -314.36M▲ 23.9% | -297.06M▲ 5.5% | -391.53M▼ 31.8% | -377.29M▲ 3.6% | -384.73M▲ 0% |
| FCF Margin % | -673.92% | -329.93% | -324.64% | - | - | -2207.58% | -1107.49% | -1072.73% | -698.33% | -582.5% |
| FCF Growth % | -1111.83% | -7.43% | -22.92% | 20.36% | -35.49% | 23.9% | 5.5% | -31.8% | 3.64% | 4.72% |
| FCF per Share | -6.22 | -5.42 | -6.38 | -4.42 | -6.83 | -5.74 | -5.34 | -6.76 | -6.51 | -6.51 |
| FCF Conversion (FCF/Net Income) | 0.91x | 0.88x | 0.90x | 0.89x | -0.25x | 1.34x | 0.84x | -0.58x | 0.90x | 0.91x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 16.08M | 0 | 1.57M | 43.15M | 628K | -871K |
AGIO Key Ratios
Agios Pharmaceuticals, Inc. (AGIO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -85.73% | -65.1% | -61.97% | -62.95% | 189.74% | -19.38% | -36.83% | 57.29% | -30.2% | -34.11% |
| Return on Invested Capital (ROIC) | - | - | -115.15% | -47.96% | -36.31% | -26.13% | -31.88% | -27.57% | -26.35% | -26.35% |
| Gross Margin | -580.48% | 98.52% | 98.88% | - | - | 88.03% | 64.57% | 88.59% | 78.67% | 82.07% |
| Net Margin | -731.6% | -366.61% | -348.97% | - | - | -1627.82% | -1312.63% | 1845.92% | -764.01% | -639.84% |
| Debt / Equity | - | - | 0.18x | 0.26x | 0.08x | 0.08x | 0.09x | 0.04x | 0.05x | 0.05x |
| Interest Coverage | - | - | - | -18.47x | - | - | - | - | - | - |
| FCF Conversion | 0.91x | 0.88x | 0.90x | 0.89x | -0.25x | 1.34x | 0.84x | -0.58x | 0.90x | 0.91x |
| Revenue Growth | -38.46% | 119.45% | 24.92% | -100% | - | - | 88.36% | 36.07% | 48.03% | 78.34% |
AGIO SEC Filings & Documents
Agios Pharmaceuticals, Inc. (AGIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
AGIO Frequently Asked Questions
Agios Pharmaceuticals, Inc. (AGIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Agios Pharmaceuticals, Inc. (AGIO) reported $66.0M in revenue for fiscal year 2025. This represents a 202% increase from $21.8M in 2011.
Agios Pharmaceuticals, Inc. (AGIO) grew revenue by 48.0% over the past year. This is strong growth.
Agios Pharmaceuticals, Inc. (AGIO) reported a net loss of $422.6M for fiscal year 2025.
Dividend & Returns
Agios Pharmaceuticals, Inc. (AGIO) has a return on equity (ROE) of -30.2%. Negative ROE indicates the company is unprofitable.
Agios Pharmaceuticals, Inc. (AGIO) had negative free cash flow of $384.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More AGIO
Agios Pharmaceuticals, Inc. (AGIO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates